The global bioburden testing market size is expected to reach USD 3.22 billion by 2030, registering a CAGR of 14.3% during the forecast period, according to a new report by Grand View Research, Inc. The market is expected to showcase upward trend in the forthcoming years owing to growing concerns about product safety. This has led to various government initiatives to promote microbiological safety testing tools.
A number of publications released by organizations to promote awareness regarding microbiological safety testing is broadening the future growth prospects of bioburden testing. For instance, the U.S. Department of Health and Human Services and Centers for Disease Control published Biosafety in Microbiological and Biomedical Laboratories (BMBL), which includes information pertaining to laboratory biosecurity and risk assessment, decontamination and sterilization, and biological toxins and biosafety levels in laboratories.
Growth of pharmaceutical, biotechnology, medical device, and food and beverage industries have contributed to the high growth of the bioburden testing market. In addition, increase in R&D investments by prominent companies is expected to encourage end users to adopt highly efficient bioburden testing tools to counter possible losses due to microbial contamination. Moreover, requirement for basic drug safety data requirements for preclinical studies is expected to fuel the demand for bioburden testing tools.
Request a free sample copy or view report summary: Bioburden Testing Market Report
On the basis of product, consumables segment dominated the market in 2023 owing to a wide use of culture media and reagents and kits.
The PCR instruments facilitate rapid analysis of bacterial bioburden, thus, fostering high market growth.
The aerobic count-testing held largest market share in 2023 due to easy isolation of aerobic bacteria by culture media.
Raw material testing is anticipated to showcase lucrative growth during the forecast period owing to the increasing number of product recalls and concern regarding product quality.
On the basis of end-use, pharmaceutical and biotechnology companies dominated the market in 2023 owing to the high growth of this industry.
The number of CMOs is increasing significantly, which has led to a rise in outsourcing services, thus, driving the segment growth.
North America held the largest revenue share in 2023 due to high R&D spending by key companies and high healthcare spending in the U.S.
Grand View Research has segmented the global bioburden testing market based on product, test, application, end-use, and region:
Bioburden Testing Product Outlook (Revenue, USD Million, 2018 - 2030)
Consumables
Culture Media
Reagents and Kits
Instruments
Automated Microbial Identification Systems
PCR Instruments
Bioburden Testing Test Outlook (Revenue, USD Million, 2018 - 2030)
Aerobic Count Testing
Anaerobic Count Testing
Fungi/ Mold Count Testing
Spore Count Testing
Bioburden Testing Application Outlook (Revenue, USD Million, 2018 - 2030)
Raw Material Testing
Medical Device Testing
In-process Material Testing
Sterilization Validation Testing
Equipment Cleaning Validation
Bioburden Testing End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology Companies
Medical Device Manufacturers
Contract Manufacturing Organizations
Manufacturers of Food & Beverage and Agricultural Products
Microbial Testing Laboratories
Bioburden Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
KSA
UAE
South Africa
Kuwait
List of Key Players in the Bioburden Testing Market
Charles River Laboratories
Merck KGaA
SGS Société Générale de Surveillance SA.
WuXi AppTec
BD
North American Science Associates, LLC
Nelson Laboratories, LLC
Thermo Fisher Scientific Inc
BIOMÉRIEUX
Pacific Biolabs
"The quality of research they have done for us has been excellent..."